Targeted therapy in bronchial asthma. Benralizumab: focus on patients using systemic glucocorticosteroids

Targeted therapy in bronchial asthma. Benralizumab: focus on patients using systemic glucocorticosteroids

A severe course of bronchial asthma develops in 5–20% of patients with bronchial asthma. The use of key disease-modifying agents for the treatment of severe bronchial asthma (SBA) is not always effective due to the possible uncontrolled course of the disease and persistence of signs of eosinophilic...

Full description

Bibliographic Details
Main Authors: N. P. Kniajeskaia, E. Kh. Anaev, A. A. Kameleva, E. V. Safoshkina, N. D. Kirichenko
Format: Article
Language:Russian
Published: Remedium Group LLC 2020-11-01
Series:Медицинский совет
Subjects:
bronchial asthma
phenotypes
endotypes
eosinophils
interleukins
monoclonal antibodies
targeted therapy
antiil-5-rα therapy
benralizumab
Online Access:https://www.med-sovet.pro/jour/article/view/5871

Internet

https://www.med-sovet.pro/jour/article/view/5871

Similar Items